Success Metrics

Clinical Success Rate
85.2%

Based on 23 completed trials

Completion Rate
85%(23/27)
Active Trials
0(0%)
Results Posted
30%(7 trials)
Terminated
4(9%)

Phase Distribution

Ph not_applicable
4
9%
Ph phase_4
23
51%
Ph phase_2
4
9%
Ph phase_3
10
22%
Ph phase_1
1
2%

Phase Distribution

1

Early Stage

4

Mid Stage

33

Late Stage

Phase Distribution42 total trials
Phase 1Safety & dosage
1(2.4%)
Phase 2Efficacy & side effects
4(9.5%)
Phase 3Large-scale testing
10(23.8%)
Phase 4Post-market surveillance
23(54.8%)
N/ANon-phased studies
4(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.7%

23 of 33 finished

Non-Completion Rate

30.3%

10 ended early

Currently Active

0

trials recruiting

Total Trials

45

all time

Status Distribution
Completed(23)
Terminated(10)
Other(12)

Detailed Status

Completed23
unknown12
Withdrawn6
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
45
Active
0
Success Rate
85.2%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.4%)
Phase 24 (9.5%)
Phase 310 (23.8%)
Phase 423 (54.8%)
N/A4 (9.5%)

Trials by Status

unknown1227%
completed2351%
terminated49%
withdrawn613%

Recent Activity

0 active trials
Showing 5 of 45
withdrawnnot_applicable

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

NCT00051090
terminatedphase_3

Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection

NCT02058108
unknownphase_4

Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B

NCT02774837
completedphase_4

Renoprotective Effects of Telbivudine in Chronic Hepatitis B

NCT03778567
completedphase_4

Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

NCT01379508
View all 45 trials

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more
NCT00051090Not Applicable

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Withdrawn
NCT02058108Phase 3

Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection

Terminated
NCT02774837Phase 4

Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B

Unknown
NCT03778567Phase 4

Renoprotective Effects of Telbivudine in Chronic Hepatitis B

Completed
NCT01379508Phase 4

Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Completed
NCT00537537Phase 4

To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)

Completed
NCT00467545Phase 4

An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B

Completed
NCT00646503Phase 4

Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

Completed
NCT00128544Phase 2

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Completed
NCT00640588Phase 3

Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

Completed
NCT00781105Phase 4

Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B

Completed
NCT00132652Phase 3

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

Completed
NCT02447705Phase 2

Replacement of Lamivudine by Telbivudine to Improve Renal Function

Completed
NCT01595685Phase 3

Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

Completed
NCT02894554Phase 4

Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

Terminated
NCT02049736Not Applicable

Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases

Withdrawn
NCT02826070Phase 4

EFFORT Further Extension Study

Unknown
NCT00970216

Study of Telbivudine in Chronic Hepatitis B

Completed
NCT02615639Phase 1

A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB

Unknown
NCT01260610Not Applicable

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
45